Guggenheim analyst Debjit Chattopadhyay initiated coverage of Voyager Therapeutics with a Buy rating and $22 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Snowflake, MongoDB downgraded to Sell: Wall Street’s top analyst calls
- Voyager Therapeutics initiated with a Buy at H.C. Wainwright
- Voyager Therapeutics appoints Toby Ferguson as CMO
- Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
- Voyager Therapeutics initiated with a Buy at Citi
